Drreddys Laboratories | RDY - Operating Expenses


Drreddys Laboratories reported INR72.94B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Bayer EUR 10.2B 523M Sep/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Cipla INR 60.98B 1.06B Dec/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Hikma Pharmaceutical USD 642M 663M Jun/2025
Lonza CHF 3.09B 564M Dec/2024
Novartis USD 9.86B 115M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Prestige Brands USD 194.44M 16.67M Sep/2025
Richter Gedeon HUF 151.11B 1.91B Sep/2025
Sun Pharmaceuticals INR 111.11B 6.97B Sep/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025